AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34781913 — intervention group
Group type: COMPARATOR
Intervention: Retinal blood flow among the four groups
Number of subjects: 79
Study 34781989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN)
Number of subjects: 100
Study 34781989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34781991 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-Fr diameter calibration bougie
Number of subjects: 0
Study 34781991 — intervention group
Group type: COMPARATOR
Intervention: 34 to 38-Fr diameter calibration bougie (standard care)
Number of subjects: 0
Study 34781991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (48-Fr and 34 to 38-Fr)
Number of subjects: 0
Study 34782015 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional intervention (dietary counseling and a nutrition plan before discharge, combined with two home visits over 4 weeks)
Number of subjects: 40
Study 34782015 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional intervention
Number of subjects: 40
Study 34782015 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 40
Study 34782339 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chronic conditions and geriatric syndromes
Number of subjects: 740
Study 34782339 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (geriatric syndrome)
Number of subjects: 740
Study 34782339 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity clusters identified
Number of subjects: 740
Study 34782339 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level variables
Number of subjects: 740
Study 34782341 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted nipple-sparing mastectomy (RNSM)
Number of subjects: 12
Study 34782428 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus intensity-modulated radiotherapy (IMRT)
Number of subjects: 25
Study 34782683 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red blood cell transfusion (mean 2.93 ± 3.05 units)
Number of subjects: 282
Study 34782683 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusion (control group)
Number of subjects: 282
Study 34782683 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red blood cell transfusion
Number of subjects: 282
Study 34783663 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartband and smartphone intervention with mindfulness exercises
Number of subjects: 100
Study 34783675 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app called PurUmeed Aaghaz
Number of subjects: 300
Study 34783675 — intervention group
Group type: COMPARATOR
Intervention: Standard face-to-face counseling
Number of subjects: 300
Study 34783716 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic agents for VHL-related ccRCC
Number of subjects: 0
Study 34783716 — intervention group
Group type: COMPARATOR
Intervention: Expert-opinion-based protocols
Number of subjects: 0
Study 34783978 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap syndrome (OVS) patients
Number of subjects: 252
Study 34784056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab (NIVO + IPI)
Number of subjects: 28
Study 34784242 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure patients
Number of subjects: 18
Study 34784242 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis patients
Number of subjects: 18
Study 34784301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis treatment
Number of subjects: 0
Study 34784301 — intervention group
Group type: COMPARATOR
Intervention: CKD without dialysis
Number of subjects: 0
Study 34784359 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular baroreflex amplification (EVBA)
Number of subjects: 14
Study 34784492 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor
Number of subjects: 0
Study 34784496 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34784657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 894
Study 34784657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower BMI
Number of subjects: 894
Study 34784657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with worse renal function
Number of subjects: 894
Study 34784815 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 106
Study 34784815 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI
Number of subjects: 106
Study 34784815 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 106
Study 34784941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.7μg/kg)
Number of subjects: 120
Study 34784941 — intervention group
Group type: COMPARATOR
Intervention: Propofol (0.5 mg/kg)
Number of subjects: 120
Study 34784953 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention (including quality improvement coaching, EHR support, training, and expert consultation)
Number of subjects: 35
Study 34784953 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth services plus ongoing practice facilitation
Number of subjects: 35
Study 34784953 — intervention group
Group type: COMPARATOR
Intervention: Continued practice facilitation alone
Number of subjects: 35
Study 34784953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for AUD or referral for AUD services
Number of subjects: 35
Study 34785305 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiding Good Choices (GGC) parenting intervention
Number of subjects: 3750
Study 34785305 — intervention group
Group type: COMPARATOR
Intervention: Usual pediatric primary care practice
Number of subjects: 3750
Study 34785541 — intervention group
Group type: EXPERIMENTAL
Intervention: TechCare App intervention (6-week duration, personalized guided self-help based on CBT principles)
Number of subjects: 16
Study 34785541 — intervention group
Group type: EXPERIMENTAL
Intervention: TechCare App intervention
Number of subjects: 16
Study 34785540 — intervention group
Group type: EXPERIMENTAL
Intervention: Alopecia areata (AA) patients
Number of subjects: 5200000
Study 34785545 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 80
Study 34785545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34785663 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication-competent SARS-CoV-2 in extrapulmonary organs
Number of subjects: 13
Study 34785663 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 genome diversity and mutations
Number of subjects: 13
Study 34785663 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral loads in lungs and plasma
Number of subjects: 13
Study 34785698 — intervention group
Group type: EXPERIMENTAL
Intervention: WT2725 dosing emulsion
Number of subjects: 0
Study 34786087 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided drug coated balloon (DCB)
Number of subjects: 54
Study 34786477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib, 300 mg
Number of subjects: 75
Study 34786477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib, 150 mg
Number of subjects: 75
Study 34786477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 34786649 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Ornithine phenylacetate
Number of subjects: 0
Study 34786667 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide p5+14 radiolabeled with iodine-124, single intravenous infusion
Number of subjects: 3
Study 34786746 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) using centrifugation technique
Number of subjects: 185
Study 34786746 — intervention group
Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 185
Study 34786746 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 185
Study 34786868 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 225
Study 34786868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 34786868 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (original mismatch cohort)
Number of subjects: 225
Study 34786868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (original mismatch cohort)
Number of subjects: 225
Study 34787462 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial profiles of NSCLC patients
Number of subjects: 121
Study 34787462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined machine learning model using both microbiota
Number of subjects: 121
Study 34787462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum microbiota
Number of subjects: 121
Study 34787462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa abundance in brain metastasis
Number of subjects: 121
Study 34787590 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated treatment (AT)
Number of subjects: 500
Study 34787590 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 500
Study 34787803 — intervention group
Group type: EXPERIMENTAL
Intervention: BREST score
Number of subjects: 1386
Study 34787803 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDICA score
Number of subjects: 1386
Study 34788228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosyntropin infusion (ACTH(1-24))
Number of subjects: 17
Study 34788228 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 17
Study 34788228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosyntropin infusion
Number of subjects: 17
Study 34788338 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Triage program (digital triage platform for pediatric sepsis)
Number of subjects: 0
Study 34788338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of Smart Triage program
Number of subjects: 0
Study 34788401 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH)
Number of subjects: 26
Study 34788416 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless VVI
Number of subjects: 6219
Study 34788416 — intervention group
Group type: COMPARATOR
Intervention: Transvenous VVI
Number of subjects: 6219
Study 34788455 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood ALL survivors
Number of subjects: 507
Study 34788455 — intervention group
Group type: COMPARATOR
Intervention: General population controls
Number of subjects: 507
Study 34788455 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners of male survivors
Number of subjects: 507
Study 34788455 — intervention group
Group type: COMPARATOR
Intervention: Partners of general population controls
Number of subjects: 507
Study 34788455 — intervention group
Group type: EXPERIMENTAL
Intervention: Female survivors (age at diagnosis 10-17 years)
Number of subjects: 507
Study 34788488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix
Number of subjects: 228233
Study 34788488 — intervention group
Group type: EXPERIMENTAL
Intervention: RotaTeq
Number of subjects: 228233
Study 34788488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotasiil
Number of subjects: 228233
Study 34788488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavac
Number of subjects: 228233
Study 34788507 — intervention group
Group type: EXPERIMENTAL
Intervention: SPK-8011 (AAV vector)
Number of subjects: 18
Study 34788506 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with an α-L-iduronidase (IDUA)-encoding lentiviral vector after myeloablative conditioning
Number of subjects: 8
Study 34788603 — intervention group
Group type: EXPERIMENTAL
Intervention: Large SOVi group
Number of subjects: 1554
Study 34788603 — intervention group
Group type: COMPARATOR
Intervention: Medium SOVi group
Number of subjects: 1554
Study 34788603 — intervention group
Group type: COMPARATOR
Intervention: Small SOVi group
Number of subjects: 1554
Study 34788804 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity index (9 chronic diseases)
Number of subjects: 3842
Study 34788804 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty index (FI) based on deficit accumulation
Number of subjects: 3842
Study 34789141 — intervention group
Group type: EXPERIMENTAL
Intervention: 40g starch from white wheat bread
Number of subjects: 1764
Study 34789141 — intervention group
Group type: EXPERIMENTAL
Intervention: 80g starch from white wheat bread
Number of subjects: 1764
Study 34789141 — intervention group
Group type: EXPERIMENTAL
Intervention: High starch intake
Number of subjects: 1764
Study 34789141 — intervention group
Group type: EXPERIMENTAL
Intervention: Low starch intake
Number of subjects: 1764
Study 34789141 — intervention group
Group type: COMPARATOR
Intervention: Control group (low AMY1 CN)
Number of subjects: 1764
Study 34789156 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma soluble urokinase plasminogen activator receptor (suPAR) levels ≥ 14.7 ng/mL
Number of subjects: 282
Study 34789156 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical complications present
Number of subjects: 282
Study 34789156 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR
Number of subjects: 282
Study 34789304 — intervention group
Group type: COMPARATOR
Intervention: Highly malignant EEG pattern
Number of subjects: 489
Study 34789304 — intervention group
Group type: COMPARATOR
Intervention: Malignant EEG pattern
Number of subjects: 489
Study 34789304 — intervention group
Group type: COMPARATOR
Intervention: Background EEG frequency of predominant delta waves or undetermined
Number of subjects: 489
Study 34789304 — intervention group
Group type: COMPARATOR
Intervention: Combination of highly malignant or malignant EEG pattern with background frequency of delta waves or undetermined
Number of subjects: 489
Study 34789490 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria diagnosis using blood samples from participants >3 months old
Number of subjects: 2690
Study 34789490 — intervention group
Group type: EXPERIMENTAL
Intervention: Serology for SARS-CoV-2 IgG antibodies introduced in 2020
Number of subjects: 2690
Study 34789494 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weekly singing sessions facilitated by Breathe Arts Health Research
Number of subjects: 400
Study 34789494 — intervention group
Group type: COMPARATOR
Intervention: Non-singing sessions in the community or online for 10 weeks
Number of subjects: 400
Study 34789498 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancestry-matched T2D genetic risk scores (GRSeur)
Number of subjects: 1513
Study 34789498 — intervention group
Group type: COMPARATOR
Intervention: Ancestry-matched or cross-ancestry GRS
Number of subjects: 1513
Study 34789774 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning (DL) network for predicting early on-treatment response in mCRC.
Number of subjects: 1028
Study 34789774 — intervention group
Group type: COMPARATOR
Intervention: Size-based methodology for predicting early on-treatment response in mCRC.
Number of subjects: 1028
Study 34789774 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of DL network with size-based methodology.
Number of subjects: 1028
Study 34789848 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-free neuroimaging
Number of subjects: 2
Study 34790142 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psycho-educational training program on positive emotion regulation (ER)
Number of subjects: 30
Study 34790237 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics as adjunctive therapy to NSPT
Number of subjects: 7
Study 34790261 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy
Number of subjects: 40
Study 34790348 — intervention group
Group type: EXPERIMENTAL
Intervention: Seralutinib (inhaled), administered for 24 weeks
Number of subjects: 80
Study 34790348 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered for 24 weeks
Number of subjects: 80
Study 34790371 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg once daily) plus S-1 (40-60 mg twice daily on days 1-14)
Number of subjects: 37
Study 34790371 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus S-1
Number of subjects: 37
Study 34790686 — intervention group
Group type: COMPARATOR
Intervention: Triglyceride-related markers
Number of subjects: 0
Study 34790722 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by surgery
Number of subjects: 185
Study 34790722 — intervention group
Group type: COMPARATOR
Intervention: Non-pCR group (subclassified into ypTanyN0M0, ypT0NanyM0, ypTanyNanyM0)
Number of subjects: 185
Study 34790722 — intervention group
Group type: EXPERIMENTAL
Intervention: pCR after nCRT
Number of subjects: 185
Study 34790722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph-node status
Number of subjects: 185
Study 34791490 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication strategies for introducing new clinical practices
Number of subjects: 61
Study 34791571 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange with albumin replacement (PE-A) 5%
Number of subjects: 13
Study 34791634 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (TA-ER) 32 mg
Number of subjects: 292
Study 34791634 — intervention group
Group type: COMPARATOR
Intervention: Conventional triamcinolone acetonide crystalline suspension (TAcs) 40 mg
Number of subjects: 292
Study 34791634 — intervention group
Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 292
Study 34791718 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal CYP2B6 activity (n=64)
Number of subjects: 173
Study 34791755 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel low-dose paclitaxel-coated balloon with citrate-based excipient (Agent PCB)
Number of subjects: 125
Study 34791755 — intervention group
Group type: COMPARATOR
Intervention: Widely used paclitaxel-coated balloon with iopromide excipient (SeQuent Please PCB)
Number of subjects: 125
Study 34791888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 0
Study 34792107 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (CAPOX)
Number of subjects: 61
Study 34792470 — intervention group
Group type: EXPERIMENTAL
Intervention: Primasun Sleep Apnea Program (Verily Sleep Apnea Program)
Number of subjects: 157
Study 34792478 — intervention group
Group type: EXPERIMENTAL
Intervention: MB Plus Text Messaging (MB-TXT)
Number of subjects: 28
Study 34792477 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleassessments using a computer tablet and testing equipment shipped to participants' homes
Number of subjects: 36
Study 34792477 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleassessments
Number of subjects: 36
Study 34792479 — intervention group
Group type: EXPERIMENTAL
Intervention: OutsidePlay web-based intervention
Number of subjects: 324
Study 34792479 — intervention group
Group type: COMPARATOR
Intervention: Control group (Position Statement on Active Outdoor Play)
Number of subjects: 324
Study 34792559 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (1000 to 3000 mg) and pyruvate (1500 to 3000 mg)
Number of subjects: 42
Study 34792559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 34792559 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide and pyruvate
Number of subjects: 42
Study 34792787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 9
Study 34793256 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (dose-escalated from 200 mg to a maximum of 800 mg daily for up to 2 years)
Number of subjects: 32
Study 34793505 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSs2 vaccine
Number of subjects: 0
Study 34793505 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSs3 vaccine
Number of subjects: 0
Study 34793505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34793505 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSs2 and WRSs3 vaccines
Number of subjects: 0
Study 34793516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness (AF) without adjustment for adiposity or physical activity (PA)
Number of subjects: 841
Study 34793516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness (AF) with adjustment for physical activity (PA)
Number of subjects: 841
Study 34793516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness (AF) with adjustment for adiposity
Number of subjects: 841
Study 34793516 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness (AF) with adjustment for both adiposity and physical activity (PA)
Number of subjects: 841
Study 34793516 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 841
Study 34793647 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation (RFD)
Number of subjects: 331
Study 34793719 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent evorpacept (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg once per week; 30 mg/kg once every other week)
Number of subjects: 110
Study 34793719 — intervention group
Group type: EXPERIMENTAL
Intervention: Evorpacept plus pembrolizumab (200 mg every 3 weeks)
Number of subjects: 110
Study 34793719 — intervention group
Group type: EXPERIMENTAL
Intervention: Evorpacept plus trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks)
Number of subjects: 110
Study 34793719 — intervention group
Group type: EXPERIMENTAL
Intervention: Evorpacept (30 mg/kg once every other week)
Number of subjects: 110
Study 34793719 — intervention group
Group type: EXPERIMENTAL
Intervention: Evorpacept (10 mg/kg once per week)
Number of subjects: 110
Study 34793719 — intervention group
Group type: EXPERIMENTAL
Intervention: Evorpacept plus pembrolizumab
Number of subjects: 110
Study 34793923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plaque features (matrix, intraplaque hemorrhage [IPH], wall thickness, plaque burden) and clinical features (age, body mass index, lipid levels)
Number of subjects: 221
Study 34793923 — intervention group
Group type: COMPARATOR
Intervention: Percent diameter stenosis
Number of subjects: 221
Study 34793923 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected predictive model including IPH and wall remodeling
Number of subjects: 221
Study 34793923 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation dataset model
Number of subjects: 221
Study 34793964 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0